[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620776":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":31,"locations":37,"responsibleParty":79,"collaborators":13,"id":81,"slug":13,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":13,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":13,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":40,"whyStopped":13,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Vanda Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs)","Safety will be assessed based on frequency of treatment-emergent adverse events and serious adverse events, and frequency of clinically notable abnormal vital signs, blood chemistry, hematology, urology, and ECGs","Through study completion, approximately 1 year",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":22,"interventionNames":24},"Ponesimod","EXPERIMENTAL",[25],"Drug: Ponesimod",[27],{"type":28,"name":22,"description":29,"armGroupLabels":30,"otherNames":13},"DRUG","Oral Tablet",[22],[32],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Vanda Pharmaceuticals, Inc.","CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[38,52,61,70],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":13},"Vanda Investigational Site","RECRUITING","Glendale","Arizona","85308","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-112.18599,33.53865,{"lat":50,"lon":49},{"facility":39,"status":40,"city":53,"state":54,"zip":55,"country":44,"countryCode":45,"cosmosGeoPoint":56,"geoPoint":60,"contacts":13},"Fremont","California","94538",{"type":47,"coordinates":57},[58,59],-121.98857,37.54827,{"lat":59,"lon":58},{"facility":39,"status":40,"city":62,"state":63,"zip":64,"country":44,"countryCode":45,"cosmosGeoPoint":65,"geoPoint":69,"contacts":13},"Rochester","New York","14623",{"type":47,"coordinates":66},[67,68],-77.61556,43.15478,{"lat":68,"lon":67},{"facility":39,"status":40,"city":71,"state":72,"zip":73,"country":44,"countryCode":45,"cosmosGeoPoint":74,"geoPoint":78,"contacts":13},"Spokane","Washington","99202",{"type":47,"coordinates":75},[76,77],-117.42908,47.65966,{"lat":77,"lon":76},{"type":80,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100620776",false,"NCT07362017","Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female subjects aged 18-65 years, inclusive\n* BMI \\>18 and \\\u003C40\n* Minimum affected BSA of 10%\n* PASI score ≥ 12\n* PGA ≥ 3\n* Diagnosed with moderate-to-severe plaque psoriasis\n\nExclusion Criteria:\n\n* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis\n* History of an allergic reaction or known and\u002For significant sensitivity to study drug","ALL","18 Years","65 Years",{"count":91,"type":92},300,"ESTIMATED","INTERVENTIONAL",[95],"PHASE3","An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis",[98],"Moderate-to-severe Chronic Plaque Psoriasis",[100,101],"psoriasis","Moderate-to-severe chronic plaque psoriasis","2026-06-10",{"date":104,"type":105},"2026-06-11","ACTUAL",{"date":107,"type":105},"2026-02-17",{"date":109,"type":92},"2028-12",{"name":5,"class":6},4]